SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Additional Listing

3 Feb 2020 12:00

RNS Number : 6333B
Consort Medical PLC
03 February 2020
 

 

 

 

3 February 2020

 

Consort Medical plc ("the Company")

 

 

Additional listing

 

Application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 366,863 Ordinary Shares of 10 pence each ("Shares") to be admitted to the Official List. The Shares are to be issued to satisfy the exercise of options under the Company's 2015 Performance Share Plans, and the listing relates to the balance of Shares not available to be drawndown under the Company's existing block listings in place for the plan.

The Shares will rank pari passu with the existing issued Ordinary Shares of the Company, and it is expected that admission to trading in the Shares will become effective on 4 February 2020.

Following the issue of the Shares, the Company will have 49,731,097 Ordinary shares in issue. There are no shares held in treasury.

 

 

 

 

Enquiries: 

Consort Medical

Tel: +44 (0) 1442 867920

Andrew Jackson - Group Counsel and Company Secretary

 

About Consort Medical plc

 

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses:

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ approximately 2,000 people globally of which approximately 1,400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSKZGFMKMMGGZM
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.